As new RFAs are announced, this page will be updated with the relevant information.
To stay up to date on awards as they become available, you can sign up below to receive RFA notifications by email. See current RFA/RFPs below.
RFA Notification List Sign Up
PCF Research Awards Notification If you would like to be notified when the next research RFA is available, please provide your contact information.
Request for Applications: PCF Young Investigator Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a request for applications for Young Investigator Awards. We especially encourage young investigators working on prostate cancer health disparities to apply.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Day, typically held in October, throughout the duration of their award.
PCF seeks applications from the global biomedical research community. Applicants traditionally under-represented in science and medicine are highly encouraged. We seek applications from early-career basic scientists, medical oncologists, pathologists, urologists, radiologists, radiation oncologists, public health experts, bioinformaticians, bioengineers, or professionals from any other field that could contribute to the end of prostate cancer. Applicants may be working in basic, translational, computational or clinical research and need not be trained specifically in prostate cancer research to be highly competitive. However, successful applicants should be working in an academic research environment capable of supporting transformational prostate cancer research. Access to and real-time interaction with a clinical environment and translational prostate cancer physician-scientists is highly desired.
Research proposals submitted in consideration for this award should, if successful, provide high impact to the field. “Small-step” or incremental proposals are usually non-competitive. Highly innovative basic science programs will be carefully considered, but priority will be given to “bench to bedside” translational research proposals with the potential to deliver near term benefit to patients.
Veterans Administration (VA) Hospital Applicants and Projects
In order to improve the health and wellness of our treasured US military veterans, applicants with Veterans Administration (VA) appointments are highly encouraged to apply. Projects that involve a VA Medical Center in their research proposal planning will be appreciated. This may include but is not limited to (1) creation of defined cohorts of prostate cancer patients annotated with the VA electronic medical record for the purpose of population science research; (2) blood, tissue or other body fluid specimens collection from VA prostate cancer patients for translational or clinical trial correlate research; (3) development of new biotechnologies for the diagnosis or treatment of prostate cancer patients within the VA healthcare system; (4) activation of novel IRB- and FDA-approved phase 1 and 2 clinical investigations; (5) unique genomic investigations of tumor or germline specimens from VA prostate cancer patients with the goal of understanding the unique mutations that might have occurred due to battlefield exposure to specific toxic materials; (6) precision medicine clinical trials matching pathogenic germline or tumor alterations to experimental or FDA-approved medications.
Visit https://pcf.smartsimple.com on or after January 31, 2020, complete the online application form and attach the PDFs.
Application Deadline: Monday, March 23, 2020, Eastern Daylight Time (EDT)
The Prostate Cancer Foundation (PCF) and Pfizer, Inc. are proud to announce the PCF-Pfizer Global Challenge Awards, a competitive, peer-reviewed Investigator Sponsored Research (ISR) grants program.
Approximately $2 million USD is allocated to this research grants program focused on investigating talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in prostate cancer.
Through this funding mechanism, PCF and Pfizer will support approximately three (3) innovative clinical investigations or clinical trial correlative research studies surrounding the use of talazoparib in prostate cancer.
Applications will be peer-reviewed by an independent review panel led by PCF, composed of expert academic researchers in order to select the most impactful studies for funding. The amount of each award will be determined based on the external review panel’s evaluation of each project.
- RFP release date: September 26, 2019
- Letter of Intent (LOI) due date: December 3, 2019, midnight Eastern Time (New York, GMT -5).
- Anticipated LOI Notification Date: January 21, 2020
- Only accepted LOIs will be invited to submit full proposals.
- Full Proposal Deadline: March 23, 2020, midnight Eastern Time (New York, GMT -5).
- Anticipated Full Proposal Notification Date: May 28, 2020
How to Apply:
Please go to www.cybergrants.com/pfizer/loi and sign in. The Letter of Intent (LOI) will be accepted via the online application.
First-time users should click “REGISTER NOW.” Select the following Competitive Grant Program Name: 2019 Oncology G – PCF-Pfizer Global Challenge Awards. Complete all required sections of the online application. See Appendix A in the RFP for additional details.
If you encounter any technical difficulties with the website, please click the ‘Technical Questions’ link at the bottom of the page.